Viewing nowSamsung Pregabalin Capsule 150mg
Pregabalin 150mg
Hard capsule · Prescription medication
Samsung Pharmaceutical Co., Ltd.

MFDS item code 201603280 · Approved 2016.06.08 · Insurance code 642306770
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment for partial-onset seizures
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also effective as an adjunct for partial seizures in epilepsy patients, whether or not they have secondary generalized symptoms. Additionally, it is used to improve symptoms of fibromyalgia. In summary, it is used for the treatment of neuropathic pain, partial seizures of epilepsy, and fibromyalgia.
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted primarily by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained using the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function ≥60: starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as indicated in the dosing regimen. b: Supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication can increase the risk of suicidal thoughts or actions, so if depression or mood changes occur during treatment, it is essential to inform a healthcare professional. This medication should not be administered to patients with hypersensitivity to this drug or those with genetic problems such as lactose intolerance. Diabetic patients may need to adjust their blood glucose control medications due to weight gain. If symptoms of angioedema, such as swelling of the face or around the mouth, occur, the medication should be discontinued immediately. Elderly patients are at higher risk of accidents such as falls due to side effects like dizziness or drowsiness and should be cautious. Blurred vision or changes in vision may occur, and these symptoms can improve upon discontinuation of the medication. Abrupt cessation of the medication may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so it should be discussed with a healthcare provider. Patients with a history of substance abuse have a higher risk of misuse or dependence on this medication, so caution is advised. Patients with impaired kidney function may require dosage adjustments. Patients with heart disease should be cautious as there may be an increased risk of heart failure when taking this medication. Caution should be exercised since central nervous system depressant effects may occur when taken with opioid analgesics. Patients with compromised respiratory function or elderly patients may face a significant risk of severe respiratory depression, and they should consult their healthcare provider. During early pregnancy, there is a risk of fetal malformations, so women who are pregnant or planning to become pregnant must consult their healthcare provider and use effective contraception. Nursing mothers should discuss with their healthcare provider whether to discontinue breastfeeding, as this medication can be passed through breast milk and may affect the infant. Dizziness or drowsiness may occur while taking this medication, so it is advisable to avoid dangerous activities such as driving or operating machinery. Severe skin reactions may rarely occur, so if any skin abnormalities appear, discontinue the medication and inform a healthcare professional immediately. In cases of overdose, symptoms such as confusion, drowsiness, and seizures may occur, and emergency treatment, including dialysis, may be necessary. This medication should be kept out of reach of children, and it should not be transferred to other containers for safety purposes.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air or moisture ingress, and it is best kept at room temperature between 15 and 30 degrees Celsius. Maintaining appropriate storage temperatures will help preserve the medication's effectiveness for a longer duration.
A white to pale yellow powder contained in a white hard capsule with a white upper part and a white lower part
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Samsung Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.